Translating preclinical research into effective treatment protocols for individuals with cancer is a complex and challenging task. One major obstacle is the highly variable genetic makeup of tumor cells, as well as the impact of the tumor microenvironment on drug response. In order to find new clinically relevant drug combinations for colorectal cancer (CRC), researchers […]
Curesponse, which produces 3D cultures of cancerous tumors to test how to treat them, has raised $6 million from Marius Nacht’s aMoon fund and the UK’s NCL Technology Ventures fund.
A new article titled “Targeted response testing that incorporates rapid genomic analysis, for customization of treatment for a cancer patient” was featured in the Israel news outlet, The Marker. The environment in which a cancerous tumor develops affects the ability of drugs to help eradicate it. Curesponse has developed a method for prioritizing possible treatments, […]
At the 2021 prestigious conference of the American Association of Cancer Research (AACR), Curesponse presented findings that could drive significant progress in how the medical community selects cancer treatments. New interim clinical trial results, which were collected in collaboration with physicians from Sheba, Kaplan, Hadassah and Beilinson hospitals in Israel, show Curesponse’s technology can predict […]
Curesponse announced today that it has secured additional USD 8 million funding for its breakthrough precision oncology platform.
Watch the interview with Prof. Raanan Berger and Dr. Vered Bar discussing Curesponse’s unique approach to enable true precision medicine for cancer.
Curesponse and Rafael to collaborate on integrating Artificial Intelligence capabilities in precision oncology platform. This collaboration combines Rafael’s vast array of combat-proven AI and Machine Learning capabilities with Curesponse’s cutting-edge, personalized oncology technologies in the fields of Drug Response, the Tumor Microenvironment (TME), and Molecular Biology to bring a unique, accurate and combined Genomic-Functional drug […]
Join Curesponse’s presentation on their precision oncology technology at Israel’s premiere and most established life sciences conference, BIOMED, Israel, 2022.
Meet Curesponse at the American Society of Clinical Oncology (ASCO) Annual Meeting, 2022
Curesponse’s poster presented at the recent ESMO Immuno-Oncology Congress in Geneva showed the cResponse™ platform can be applied for the modeling and evaluation of immune modulating drugs in cancer tissue.The cResponse™ assay maintains the high viability of human cancer, uniquely preserving the 3D architecture together with its microenvironment, including immune cells for sufficient time to […]